查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1734895

2032 年鏈球菌咽頭炎治療市場預測：按治療類型、給藥途徑、疾病類型、通路、診斷方法、最終用戶和地區進行的全球分析

Strep Throat Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type, Route of Administration, Disease Type, Distribution Channel, Diagnosis Method, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2025 年全球鏈球菌性咽頭炎治療市場價值為 22.6 億美元，預計到 2032 年將達到 38.8 億美元，預測期內複合年成長率為 8.0%。

鏈球菌咽頭炎的治療主要包括使用抗生素清除引起感染的化膿性鏈球菌。常用的抗生素包括阿莫西林和青黴素，但過敏患者也可以使用頭孢氨芐或阿奇黴素治療。早期抗生素治療可以減輕症狀的嚴重程度和持續時間，避免風濕熱等併發症，並降低感染傳播給他人的風險。此外，支持性治療有助於控制發燒、發炎和喉嚨痛等症狀。這包括休息、補充水分以及服用對乙醯胺酚和Ibuprofen等非處方止痛藥。

根據美國疾病管制與預防中心 ( 美國) 的建議，抗生素治療 A 型鏈球菌 (GAS)咽頭炎對於縮短症狀持續時間、預防併發症和限制感染至關重要。青黴素或阿莫西林因其有效性、窄頻譜和低成本而被推薦作為一線治療藥物。

鏈球菌感染疾病盛行率不斷上升

化膿性鏈球菌，又稱為A類溶血性鏈球菌或GAS，是鏈球菌性咽喉炎的病原體。鏈球菌性咽喉炎是一種常見的細菌感染疾病，主要影響5至15歲的兒童。美國疾病管制與預防中心估計，美國每年有數百萬例輕度鏈球菌性咽頭炎感染疾病和1.1萬至2.4萬例侵襲性GAS病例。在全球範圍內，醫療保健服務可能有限的中低收入國家的負擔更為沉重。此外，由於這種持續存在的流行病，支持性治療、診斷和抗生素市場持續蓬勃發展。

抗生素過度處方和誤診

鏈球菌性咽頭炎治療市場面臨的一個主要障礙是咽喉痛的常見誤診。儘管許多咽頭炎是由病毒而非細菌引起的，但醫生經常在未進行充分檢測的情況下開立抗生素處方。這種誤診不僅會導致不必要的用藥，還會加劇抗生素抗藥性，進而降低治療效果。根據美國疾病管制與預防中心 (CDC) 統計，美國門診高達 30% 的抗生素處方是不必要的。此外，這種過度處方帶來的監管壓力和更嚴格的處方指南可能會透過減少濫用抗生素的銷售，間接抑制市場擴張。

家用快速診斷試劑盒的開發

家用快速感染疾病診斷套件的開發，源自於人們對自我檢測和分散式醫療服務的需求。與家用 COVID-19 檢測和妊娠檢測類似，數位健康和​​分子診斷技術的發展使消費者能夠使用市售套件進行感染疾病自我檢測。此外，這些技術進步有助於更早發現和治療，從而減輕臨床基礎設施的壓力，尤其是在偏遠和資源匱乏的地區。企業可以透過投資易於使用、準確且價格合理的診斷解決方案，來利用這消費者主導的市場擴張。

學名藥競爭和市場飽和

咽頭炎的治療主要依靠少數幾種已使用數十年的知名抗生素。其中許多藥物，例如阿莫西林和青黴素，都存在更便宜的學名藥。這導致了激烈的價格競爭和狹窄的淨利率，抑制了該領域的醫藥投資和創新。此外，缺乏獨特的產品也阻礙了市場擴張，導致人們高度依賴批量採購協議和公開競標，而這些方式並不總是有利可圖。

COVID-19的影響：

新冠疫情對鏈球菌性咽頭炎藥物市場造成了衝擊。一方面，佩戴口罩、保持社交距離和改善衛生習慣等預防措施的廣泛實施，顯著減少了鏈球菌性咽喉炎和其他常見呼吸道感染疾病的感染疾病。另一方面，疫情也加速了遠端醫療和家用診斷設備的普及，為感染疾病的診斷和處方治療開闢了新的途徑。此外，隨著大眾對感染疾病和抗生素管理意識的提高，處方實踐和就醫行為也發生了變化，鏈球菌性咽喉炎的管理和治療方法也與時俱進。

口服藥物市場預計將成為預測期內最大的市場

預計口服製劑領域將在預測期內佔據最大的市場佔有率。口服抗生素，尤其是青黴素和阿莫西林，因其療效確切、使用方便、價格實惠且患者依從性高，是鏈球菌咽頭炎的一線治療藥物。在門診治療方面，大多數成人和兒童患者更傾向於口服藥物，而不是注射劑或外用藥物。錠劑、膠囊和混懸液等口服製劑易於獲取，無需醫護人員監督，非常適合在資源有限的環境中使用。此外，它們的廣泛獲取和易用性也是其在鏈球菌咽頭炎治療領域廣受歡迎的原因。

預計急性鏈球菌感染疾病部分在預測期內將以最高的複合年成長率成長。

預計急性鏈球菌感染疾病領域將在預測期內達到最高成長率。 A組溶血性鏈球菌感染疾病的全球發生率不斷上升，尤其是在最容易感染急性鏈球菌感染疾病的兒童和青少年群體中，這推動了該領域的成長。擴大就地檢驗，並提高對早期診斷和適當抗生素治療的認知，有助於及時發現和治療急性感染疾病。此外，為了避免風濕熱和鏈球菌感染後腎絲球腎炎等併發症，醫護人員優先治療急性病例，增加了治療需求。

佔比最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。這得歸功於其強大的醫療保健體系、對感染疾病的高度認知以及便捷的診療服務。該地區鏈球菌感染疾病的盛行率很高，尤其是在學齡兒童中，這導致對快速診斷檢測和抗生素的需求持續成長。機構和政府對定期健康檢查、抗生素管理和早期診斷的重視進一步推動了市場擴張。此外，頂級製藥公司的入駐以及持續的研發也正在提高治療的可用性和創新性。

複合年成長率最高的地區：

預計亞太地區將在預測期內實現最高的複合年成長率。這得益於該地區人口眾多且不斷成長、感染疾病知識水平不斷提高以及醫療保健服務的便利性。在中國、印度和東南亞等國家，感染疾病和其他呼吸道感染疾病呈現上升趨勢，尤其是在年輕人和老年人口。由於政府採取措施改善初級醫療保健、提高抗生素可近性以及擴大農村地區的醫療覆蓋率，市場正在擴大。此外，由於對遠端醫療、診斷基礎設施和公共衛生計劃的投資不斷增加，該地區的市場正在迅速擴張。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球鏈球菌咽頭炎治療市場（依治療類型）

  • 抗生素
    • 阿莫西林
    • 青黴素
  • 止痛藥
  • 益生菌療法
  • 草本/天然療法
  • 其他類型的治療

6. 全球鏈球菌咽頭炎治療市場（依給藥途徑）

  • 口服
  • 話題
  • 注射

7. 全球鏈球菌咽頭炎治療市場（依疾病型態）

  • 急性鏈球菌咽頭炎
  • 咽頭炎
  • 扁桃腺炎
  • 喉炎
  • 其他類型的疾病

8. 全球鏈球菌咽頭炎治療市場（依通路）

  • 醫院藥房
  • 零售藥局
  • 網路藥局

9. 全球鏈球菌咽頭炎治療市場（依診斷方法）

  • 抗體檢測
  • 身體檢查
  • 咽喉培養
  • 快速抗原檢測試驗（RADT）

第 10 章。全球鏈球菌咽頭炎治療市場（依最終用戶分類）

  • 醫院
  • 專科診所
  • 診斷實驗室
  • 其他最終用戶

第 11 章。全球鏈球菌咽頭炎治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Bayer AG
  • GSK plc（GlaxoSmithKline）
  • Abbott Laboratories
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Melinta Therapeutics
  • Dr. Reddy's Laboratories Ltd.
  • Azurity Pharmaceuticals, Inc.
  • Mylan NV（Viatris）
  • Sandoz
  • Cipla Ltd.
  • Sun Pharmaceutical Industries Ltd.
Product Code: SMRC29532

According to Stratistics MRC, the Global Strep Throat Treatment Market is accounted for $2.26 billion in 2025 and is expected to reach $3.88 billion by 2032 growing at a CAGR of 8.0% during the forecast period. Strep throat treatment primarily involves the use of antibiotics to eliminate the Streptococcus pyogenes bacteria responsible for the infection. Commonly prescribed antibiotics include amoxicillin or penicillin, but patients with allergies may also be treated with cephalexin or azithromycin. The severity and duration of symptoms can be lessened, complications like rheumatic fever can be avoided, and the chance of infecting others is decreased with early antibiotic treatment. Moreover, supportive care can help manage symptoms like fever, inflammation, and sore throat. It includes rest, hydration, and over-the-counter pain relievers like acetaminophen or ibuprofen.

According to the Centers for Disease Control and Prevention (CDC), antibiotic treatment for group A streptococcal (GAS) pharyngitis is essential to reduce symptom duration, prevent complications, and limit transmission. Penicillin or amoxicillin is the recommended first-line therapy due to their efficacy, narrow spectrum, and low cost.

Market Dynamics:

Driver:

Growing streptococcal infection prevalence

Streptococcus pyogenes, also known as Group A Streptococcus or GAS, is the causative agent of strep throat, a common bacterial infection that primarily affects children between the ages of 5 and 15. The CDC estimates that millions of mild cases, such as strep throat, and between 11,000 and 24,000 cases of invasive GAS disease occur each year in the United States. In low- and middle-income nations where access to healthcare may be restricted, the burden is even greater globally. Additionally, the market for supportive therapies, diagnostics, and antibiotics is constantly active due to this enduring prevalence.

Restraint:

Over prescription and incorrect diagnosis of antibiotics

A major barrier to the market for strep throat treatments is the common misdiagnosis of sore throats. Antibiotics are often prescribed without adequate testing, even though many sore throats are viral rather than bacterial. The effectiveness of treatment is compromised because this not only results in needless drug use but also fuels antibiotic resistance. In outpatient settings in the United States, up to 30% of antibiotic prescriptions are unnecessary, according to the CDC. Furthermore, regulatory pressure and tighter prescription guidelines brought about by this over prescription can indirectly stifle market expansion by reducing the sale of indiscriminate antibiotics.

Opportunity:

Developments in at-home and quick diagnostics

The development of quick and at-home strep throat diagnostic kits has been prompted by the move toward self-testing and decentralization of care. Similar to home COVID-19 or pregnancy tests, consumers can now self-test for streptococcal infections using over-the-counter kits owing to developments in digital health and molecular diagnostics. Moreover, these developments facilitate early detection and treatment and lessen the strain on clinical infrastructure, particularly in isolated or resource-constrained locations. Businesses can take advantage of this expanding consumer-driven market by investing in diagnostic solutions that are easy to use, precise, and reasonably priced.

Threat:

Generic competition and market saturation

A small number of well-known antibiotics that have been used for decades dominate the market for strep throat treatments. There are inexpensive generic versions of many of these medications, including amoxicillin and penicillin. This deters significant pharmaceutical investment and innovation in this field by resulting in fierce price competition and narrow profit margins. Additionally, lack of unique products can impede market expansion and increase reliance on bulk purchasing agreements or public-sector tenders, which aren't always profitable.

Covid-19 Impact:

The COVID-19 pandemic affected the market for strep throat treatments. On the one hand, strep throat and other common respiratory infections have become much less common as a result of the widespread adoption of preventive measures like mask wearing, social distancing, and better hygiene. The pandemic, however, hastened the uptake of telemedicine and at-home diagnostic instruments, opening up new avenues for the diagnosis and prescription of strep throat remedies. Furthermore, the management and treatment of strep throat has also changed over time as a result of changes in prescribing practices and healthcare-seeking behaviour brought about by heightened public awareness of infectious diseases and antimicrobial stewardship.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to account for the largest market share during the forecast period. Due to their demonstrated effectiveness, simplicity of use, affordability, and high patient compliance, oral antibiotics-especially penicillin and amoxicillin-are the first-line treatment for strep throat. When it comes to outpatient treatment, the majority of patients-adults and children alike-prefer oral medications over inject able or topical ones. Since oral dosage forms like tablets, capsules, and suspensions are widely accessible and don't need a medical professional's supervision, they can be used even in environments with limited resources. Moreover, their widespread availability and ease of use help explain why they are so popular in the world of strep throat remedies.

The acute strep throat segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the acute strep throat segment is predicted to witness the highest growth rate. The rising incidence of Group A Streptococcus infections worldwide, especially in children and adolescents who are most susceptible to acute strep throat, is what is driving this segment's growth. The expansion of point-of-care testing and growing knowledge of early diagnosis and appropriate antibiotic treatment facilitate quicker acute infection detection and management. Additionally, in order to avoid complications like rheumatic fever and post-streptococcal glomerulonephritis, medical professionals are giving priority to acute cases, which raises the need for treatment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by a strong healthcare system, a high level of infectious disease awareness, and easy access to services for diagnosis and treatment. The high incidence of strep throat in the area, particularly in school-age children, contributes to the ongoing need for quick diagnostic tests and antibiotics. Market expansion is further supported by a strong institutional and governmental emphasis on routine health examinations, antibiotic stewardship, and early diagnosis. Furthermore, the availability and innovation of treatments are improved by the presence of top pharmaceutical companies and continuous research and development.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR because of its sizable and expanding population, increased knowledge of infectious diseases, and easier access to medical care. Strep throat and other respiratory tract infections are on the rise in countries like China, India, and Southeast Asia, especially in young people and the elderly. The market is expanding as a result of government efforts to improve primary healthcare, as well as increased access to antibiotics and healthcare outreach in rural areas. Additionally, the region's market is expanding quickly due to rising investments in telehealth, diagnostic infrastructure, and public health initiatives.

Key players in the market

Some of the key players in Strep Throat Treatment Market include Bayer AG, GSK plc (GlaxoSmithKline), Abbott Laboratories, Merck & Co., Inc., Pfizer Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd, Melinta Therapeutics, Dr. Reddy's Laboratories Ltd., Azurity Pharmaceuticals, Inc., Mylan N.V. (Viatris), Sandoz, Cipla Ltd. and Sun Pharmaceutical Industries Ltd.

Key Developments:

In March 2025, Bayer and Suzhou Puhe BioPharma Co.,Ltd announced that they have entered into a global license agreement for Puhe BioPharma's oral, small molecule PRMT5 inhibitor that selectively targets MTAP-deleted tumors. Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor.

In March 2025, Merck and Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China. Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

In December 2024, Abbott Laboratories and DexCom they have reached an agreement to settle all patent disputes between them related to continuous glucose monitoring devices. The agreement will dismiss all pending cases in courts and patent offices worldwide, along with a provision preventing legal action between the companies for patent and appearance disputes for the next 10 years.

Treatment Types Covered:

  • Antibiotics
  • Pain Relievers
  • Probiotic Therapies
  • Herbal/Natural Remedies
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Topical
  • Injectable

Disease Types Covered:

  • Acute Strep Throat
  • Pharyngitis
  • Tonsillitis
  • Laryngitis
  • Other Disease Types

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Diagnosis Methods Covered:

  • Antibody Test
  • Physical Examination
  • Throat Culture
  • Rapid Antigen Detection Tests (RADTs)

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Strep Throat Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Antibiotics
    • 5.2.1 Amoxicillin
    • 5.2.2 Penicillin
  • 5.3 Pain Relievers
  • 5.4 Probiotic Therapies
  • 5.5 Herbal/Natural Remedies
  • 5.6 Other Treatment Types

6 Global Strep Throat Treatment Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Topical
  • 6.4 Injectable

7 Global Strep Throat Treatment Market, By Disease Type

  • 7.1 Introduction
  • 7.2 Acute Strep Throat
  • 7.3 Pharyngitis
  • 7.4 Tonsillitis
  • 7.5 Laryngitis
  • 7.6 Other Disease Types

8 Global Strep Throat Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacy
  • 8.3 Retail Pharmacy
  • 8.4 Online Pharmacy

9 Global Strep Throat Treatment Market, By Diagnosis Method

  • 9.1 Introduction
  • 9.2 Antibody Test
  • 9.3 Physical Examination
  • 9.4 Throat Culture
  • 9.5 Rapid Antigen Detection Tests (RADTs)

10 Global Strep Throat Treatment Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Diagnostic Laboratories
  • 10.5 Other End Users

11 Global Strep Throat Treatment Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Bayer AG
  • 13.2 GSK plc (GlaxoSmithKline)
  • 13.3 Abbott Laboratories
  • 13.4 Merck & Co., Inc.
  • 13.5 Pfizer Inc.
  • 13.6 Novartis AG
  • 13.7 Sanofi
  • 13.8 Teva Pharmaceutical Industries Ltd
  • 13.9 Melinta Therapeutics
  • 13.10 Dr. Reddy's Laboratories Ltd.
  • 13.11 Azurity Pharmaceuticals, Inc.
  • 13.12 Mylan N.V. (Viatris)
  • 13.13 Sandoz
  • 13.14 Cipla Ltd.
  • 13.15 Sun Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Strep Throat Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Strep Throat Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Strep Throat Treatment Market Outlook, By Antibiotics (2024-2032) ($MN)
  • Table 4 Global Strep Throat Treatment Market Outlook, By Amoxicillin (2024-2032) ($MN)
  • Table 5 Global Strep Throat Treatment Market Outlook, By Penicillin (2024-2032) ($MN)
  • Table 6 Global Strep Throat Treatment Market Outlook, By Pain Relievers (2024-2032) ($MN)
  • Table 7 Global Strep Throat Treatment Market Outlook, By Probiotic Therapies (2024-2032) ($MN)
  • Table 8 Global Strep Throat Treatment Market Outlook, By Herbal/Natural Remedies (2024-2032) ($MN)
  • Table 9 Global Strep Throat Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 10 Global Strep Throat Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 11 Global Strep Throat Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 12 Global Strep Throat Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 13 Global Strep Throat Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 14 Global Strep Throat Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 15 Global Strep Throat Treatment Market Outlook, By Acute Strep Throat (2024-2032) ($MN)
  • Table 16 Global Strep Throat Treatment Market Outlook, By Pharyngitis (2024-2032) ($MN)
  • Table 17 Global Strep Throat Treatment Market Outlook, By Tonsillitis (2024-2032) ($MN)
  • Table 18 Global Strep Throat Treatment Market Outlook, By Laryngitis (2024-2032) ($MN)
  • Table 19 Global Strep Throat Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 20 Global Strep Throat Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 21 Global Strep Throat Treatment Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
  • Table 22 Global Strep Throat Treatment Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
  • Table 23 Global Strep Throat Treatment Market Outlook, By Online Pharmacy (2024-2032) ($MN)
  • Table 24 Global Strep Throat Treatment Market Outlook, By Diagnosis Method (2024-2032) ($MN)
  • Table 25 Global Strep Throat Treatment Market Outlook, By Antibody Test (2024-2032) ($MN)
  • Table 26 Global Strep Throat Treatment Market Outlook, By Physical Examination (2024-2032) ($MN)
  • Table 27 Global Strep Throat Treatment Market Outlook, By Throat Culture (2024-2032) ($MN)
  • Table 28 Global Strep Throat Treatment Market Outlook, By Rapid Antigen Detection Tests (RADTs) (2024-2032) ($MN)
  • Table 29 Global Strep Throat Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global Strep Throat Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 31 Global Strep Throat Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 32 Global Strep Throat Treatment Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 33 Global Strep Throat Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.